281results about "Living procariotic cell medical ingredients" patented technology

Aspects of the invention relate to compositions and methods for using recombinant cells to sense and destroy specific pathogens.

The present invention is directed to isolated thraustochytrid microorganisms as well as strains and mutants thereof. The invention is further directed to biomasses, microbial oils, compositions, cultures, methods of producing microbial oils, and methods of using the isolated thraustochytrids, biomasses, and microbial oils.

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.

The present invention relates to the use of F4+ non-pathogenic Escherichia coli strains to promote growth in an animal. The present invention also relates to the use of such strains to homogenize growth among a herd of animals. More specifically, the animal(s) of interest in the present invention are those wherein growth promotion or growth homogenization are desired goals, such as animals reared for meat production. The present invention further relates to a method for promoting growth of an animal as well as a method for homogenizing growth among a herd of animals.

The invention relates to lactobacillus rhamnosus CCFM1107 capable of resisting oxidation and relieving chronic alcohol liver injury and also relates to application of the lactobacillus rhamnosus CCFM1107 to preparation of dairy products by using a working fermentation agent of the lactobacillus rhamnosus CCFM1107. The dairy product is milk, milk power, milk capsule products or fermented milk containing the lactobacillus rhamnosus CCFM1107. The lactobacillus rhamnosus CCFM1107 disclosed by the invention has high oxidation resistance, the capability of removing diphenyl picrylhydrazyl (DPPH) free radical and hydroxyl free radical, the capability of inhibiting lipid peroxidation and the capabilities of tolerating cholate, sodium chloride and pH. According to the lactobacillus rhamnosus CCFM1107 disclosed by the invention, the liver functions of a mouse suffered from the chronic alcohol liver injury and the antioxidant indexes can be improved; the serum endotoxin level is reduced; the distribution of intestinal flora is adjusted; and the chronic alcohol liver injury can be effectively relieved.

Provided are compositions comprising a bacterial strain of the genus Blautia, for use in a method of increasing the microbiota diversity and / or inducing stability of the microbiota of a subject.

The invention provides compositions comprising one or more bacterial strains for treating preventing diarrhea and / or constipation.

Provided herein are Salmonella enteritidis 13A strains and compositions comprising these strains. Also provided are methods of enhancing an immune response against Influenza A and methods of reducing morbidity associated with an Influenza A infection. Methods of enhancing an immune response to a vaccine vector by expressing a polypeptide of CD 154 capable of binding CD40 are also disclosed. Methods of developing a bacterial vaccine vector are disclosed. Methods of generating scarless site-specific mutations in a bacterium are also disclosed.

The invention provides compositions comprising one or more bacterial strains for treating or preventing visceral hypersensitivity.

The invention provides compositions comprising one or more bacterial strains for treating or preventing visceral hypersensitivity.

Various embodiments of the present invention are directed to the field of Oncology, and in particular embodiments directed to a method of ameliorating, treating, or preventing a malignancy in a human subject wherein the steps of the method assist or boost the immune system in eradicating cancerous cells. In certain embodiments, administration of beneficial bacteria to an individual's microbiome that have been modified so as to produce effective amounts of desired compositions, compounds, agents, e.g. tomatidine, p53 protein, statins, etc., is employed to address cancerous conditions. In several embodiments, the administration of such beneficial bacteria and microbes to an individual's microbiome invokes either an active (or a passive) immune response to destroy, weaken or render less invasive certain cancerous cells, and preferably maintains muscle tissue to combat cancer cachexia.